Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium (Q35050239)

6 August 2017

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium (English)

1 reference

6 August 2017

phase II clinical trial

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

1 reference

dasatinib monohydrate

1 reference

1 reference

9

Everett E Vokes

1 reference

6 August 2017

Manish R Sharma

1

1 reference

6 August 2017

Kristen Wroblewski

2

1 reference

6 August 2017

Blase N Polite

3

1 reference

6 August 2017

James A Knost

4

1 reference

6 August 2017

James A Wallace

5

1 reference

6 August 2017

Sanjiv Modi

6

1 reference

6 August 2017

Bethany G Sleckman

7

1 reference

6 August 2017

David Taber

8

1 reference

6 August 2017

Walter M Stadler

10

1 reference

6 August 2017

Hedy L Kindler

11

1 reference

6 August 2017

7 May 2011

1 reference

Investigational New Drugs

6 August 2017

1 reference

6 August 2017

30

1 reference

6 August 2017

3

1 reference

6 August 2017

1211-1215

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-011-9681-x

6 August 2017

0 references

cites work

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Advances in targeting SRC in the treatment of breast cancer and other solid malignancies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Optimal two-stage designs for phase II clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4317401

Src activation regulates anoikis in human colon tumor cell lines

8 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9681-X

SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9681-X

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9681-X

Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9681-X

10.1007/S10637-011-9681-X

21 January 2018

Identifiers

DOI

1 reference

release_x4xpexlpy5aavf65x63oahxw3y

6 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x4xpexlpy5aavf65x63oahxw3y

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMCID

4317401

1 reference

6 August 2017

1 reference